Merck KGaA (FRA:MRK) Given a €108.00 Price Target at Kepler Capital Markets

Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA (FRA:MRK) in a research note released on Wednesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Other analysts have also issued reports about the stock. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Monday, November 11th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, July 30th. Barclays set a €85.00 ($98.84) price target on shares of Merck KGaA and gave the stock a sell rating in a research report on Tuesday, November 12th. Independent Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Thursday, September 19th. Finally, Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €101.88 ($118.47).

FRA MRK traded up €1.85 ($2.15) during midday trading on Wednesday, hitting €108.00 ($125.58). The company had a trading volume of 770,765 shares. The firm has a fifty day simple moving average of €105.44 and a two-hundred day simple moving average of €96.92. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: What is the 52-week high/low?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.